Identifying new targets to make cancer cells more sensitive to radiation therapy.
In vivo CRISPR-screening of novel cancer cell-intrinsic targets that sensitize to local ionizing radiation, and possible combination with systemic checkpoint blockade.
This study is exploring how to make radiation therapy work better for cancer patients by using a special technology to find and change certain genes in cancer cells, which could help the treatment be more effective and improve outcomes for those receiving radiation.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10684850 on NIH RePORTER |
What this research studies
This research investigates how to enhance the effectiveness of radiation therapy for cancer by using advanced CRISPR technology to identify genetic targets within cancer cells. The approach involves screening cancer cells to find specific genes that, when modified, can increase their sensitivity to radiation treatment. The study will utilize both mouse models and clinical data to validate these findings, aiming to improve treatment outcomes for patients undergoing radiation therapy. By understanding how these genetic changes affect the immune response, the research seeks to develop more effective combination therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who are undergoing or considering radiation therapy.
Not a fit: Patients who are not receiving radiation therapy or those with non-malignant conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments that significantly improve the effectiveness of radiation therapy for cancer patients.
How similar studies have performed: Previous research has shown promise in using genetic screening approaches to enhance cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Weichselbaum, Ralph R — University of Chicago
- Study coordinator: Weichselbaum, Ralph R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.